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Abstract
C-C chemokine receptor 7 (CCR7) contributes to the survival of certain cancer cell lines, but its role in the proliferation of
human non-small cell lung cancer (NSCLC) cells remains vague. Proliferation assays performed on A549 and H460 NSCLC
cells using Cell Counting Kit-8 indicated that activation of CCR7 by its specific ligand, exogenous chemokine ligand 21
(CCL21), was associated with a significant linear increase in cell proliferation with duration of exposure to CCL21. The CCL21/
CCR7 interaction significantly increased the fraction of cells in the G2/M phase of the cell cycle as measured by flow
cytometry. In contrast, CCL21/CCR7 had no significant influence on the G0/G1 and S phases. Western blot and real-time PCR
indicated that CCL21/CCR7 significantly upregulated expression of cyclin A, cyclin B1, and cyclin-dependent kinase 1 (CDK1),
which are related to the G2/M phase transition. The expression of cyclin D1 and cyclin E, which are related to the G0/G1 and
G1/S transitions, was not altered. The CCL21/CCR7 interaction significantly enhanced phosphorylation of extracellular signal-
regulated kinase (P-ERK) but not Akt, as measured by Western blot. LY294002, a selective inhibitor of PI3K that prevents
activation of the downstream Akt, did not weaken the effect of CCL21/CCR7 on P-ERK. Coimmunoprecipitation further
confirmed that there was an interaction between P-ERK and cyclin A, cyclin B1, or CDK1, particularly in the presence of
CCL21. CCR7 small interfering RNA or PD98059, a selective inhibitor of MEK that disrupts the activation of downstream ERK,
significantly abolished the effects of exogenous CCL21. These results suggest that CCL21/CCR7 contributes to the time-
dependent proliferation of human NSCLC cells by upregulating cyclin A, cyclin B1, and CDK1 potentially via the ERK
pathway.
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Introduction
C-C chemokine receptor 7 (CCR7) is expressed on all naive T-
cells and on some memory T-cells, B-cells, and mature dendritic
cells [1]. Upon interaction with its ligands, chemokine ligand 19
(CCL19) or chemokine ligand 21 (CCL21) [2], CCR7 contributes
to lymphocyte trafficking and homing to lymph nodes during
immune and inflammatory reactions [3–5]. CCR7 is highly
expressed in non-small cell lung cancer (NSCLC), breast cancer,
and squamous cell carcinoma of the head and neck and is
responsible for mediating metastasis in certain cancer cells lines
[6–15]. To date, the role of CCR7 in the proliferation of human
NSCLC cells has not been elucidated.
Activation of CCR7 can increase phosphorylation of extracel-
lular signal-regulated kinase (P-ERK) or Akt (P-Akt) via Gi
proteins to enhance cell proliferation or survival [16–20]. ERK
belongs to the mitogen-activated protein kinase (MAPK) family,
which also includes c-Jun N-terminal kinase ( JNK) and p38. The
ERK cascade, activated by mitogenic stimuli, is critical for
proliferation and survival [21,22] and is required for normal
progression into mitosis [23,24]. The JNK and p38 pathways are
activated in response to chemicals and environmental stress [25–
27]. Akt (also known as Akt1), a mediator of growth factor-induced
cell survival [28–30], may promote cell proliferation via
phosphorylation [31].
The purpose of this study was to examine the effect and
regulatory mechanism of the CCL21/CCR7 interaction on the
proliferation of A549 and NCI-H460 (H460) human NSCLC cells.
Here, we demonstrated that CCL21/CCR7 contributed to the
time-dependent proliferation of human NSCLC cells by upregu-
lating the expression of cyclin A, cyclin B1, and CDK1 via the
ERK pathway. Information garnered from this study lends insight
to the mechanisms of survival of CCR7-mediated cancer cells and
has implications for treatment targets in NSCLC.
Results
CCL21/CCR7 promotes proliferation of A549 and H460 cells.
In a previous study, we identified a higher CCR7 expression level
in A549 and H460 human NSCLC cell lines compared with other
cell lines [32]. To investigate the role of CCR7 in the functioning
of A549 and H460 cells, CCR7 activation and inhibition were
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RNA (siRNA), respectively. After transfection with CCR7 siRNA
(siCCR7) or control siRNA, the expression of CCR7 was
evaluated using Western blot and reverse transcriptase (RT)-
PCR. We found that siCCR7 significantly downregulated the
protein and mRNA levels of CCR7, compared with control
siRNA (Figure 1).
To determine the effect of CCL21/CCR7 on cell proliferation,
the CCK-8 assay was performed on A549 and H460 cells.
According to the published data [33,34] and the results of our
preliminary experiment, at 100 ng/mL concentrations CCL21
significantly promoted cell proliferation, compared with 50 ng/
mL concentrations, while there were no significant difference
between 100 ng/mL and 200 ng/mL concentrations (Figure 2).
Figure 1. Efficiency of CCR7 siRNA in A549 or H460 cells. A549 (A) and H460 (B) cells were transfected with control siRNA or CCR7 siRNA
(siCCR7). After transfection, the expression of CCR7 protein (a) and mRNA (b) was evaluated using Western blot (a) and RT-PCR (b) and compared to
untransfected A549 or H460 cells. Each bar represents the mean 6 SD of three independent experiments. *p,0.05, compared with control cells.
doi:10.1371/journal.pone.0021119.g001
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following experiment. The CCL21/CCR7 interaction significantly
promoted cell proliferation, whereas siCCR7 significantly abro-
gated the action of CCL21 (Figure 3). siCCR7 alone had no
significant effect on cell proliferation, compared with control cells.
Significant differences were observed between all time point
examined (all p,0.01), indicating a linear increase in proliferation
with increasing exposure times to CCL21 (all p,0.01).
CCL21/CCR7 augments the proportion of cells in G2/M. To
verify whether the action of CCL21/CCR7 on the proliferation of
A549 and H460 cells is associated with a change in cell cycle
distribution, cell cycle analysis was performed using flow
cytometry. The CCL21/CCR7 interaction significantly enhanced
the proportion of cells in the G2/M phase, whereas there was no
significant effect of this interaction on the proportion of cells in
G0/G1 or the S phase, compared with control cells (Table 1).
siCCR7 significantly abolished this effect of CCL21, whereas
siCCR7 alone had no significant effect on cell cycle distribution.
CCL21/CCR7 upregulates the expression of cyclin A, cyclin
B1, and CDK1. To determine the possible mechanism by which
CCL21/CCR7 influences the G2/M phase distribution in A549
and H460 cells, the expression of cyclins and cyclin-dependent
kinase 1 (CDK1) was assessed using Western blot and real-time
PCR. Compared with control cells, the CCL21/CCR7 interaction
significantly upregulated the protein and mRNA levels of cyclin A,
cyclin B1, and CDK1, which are related to G2/M phase
progression (Figure 4). siCCR7 significantly abrogated the effects
of CCL21, whereas siCCR7 alone had no significant effect on
cyclin or CDK1 expression. CCL21 had no significant effect on
the levels of cyclin D1 or cyclin E, which are related to G0/G1 and
the G1/S transition.
CCL21/CCR7 upregulates the expression of P-ERK but not P-
Akt. Others have reported that CCR7 may increase the
phosphorylation of ERK, JNK, or Akt, which are related to cell
survival [16–20,33,35–42]. To verify whether the CCL21/CCR7
interaction may also enhance the expression of MAPK family
members and Akt in A549 and H460 cells, the expression of these
components was assessed using Western blot. The CCL21/CCR7
interaction significantly upregulated the expression of P-ERK at
24 h and 48 h, whereas there was no significant impact on the
expression of ERK (Figure 5). CCL21/CCR7 had no significant
influence on the expression or phosphorylation of JNK, p38, or
Akt. Because Akt is possibly upstream of ERK [43], A549 and
H460 cells were treated with CCL21 for 24 h after a 1-h
exposure to LY294002, a selective inhibitor of PI3K that inhibits
activation of the downstream Akt pathway. Following this
treatment, CCL21/CCR7 still significantly upregulated the
expression of P-ERK (Figure 6).
Inhibition of P-ERK abolishes the impellent effects of CCL21/
CCR7 on proliferation and G2/M phase progression. To verify
whether PD98059, a selective inhibitor of MEK that disrupts
activation of downstream ERK, can abolish the effects of CCL21/
CCR7 on the proliferation and G2/M phase progression of A549
and H460 cells, cell viability and cell cycle distribution assays were
performed using CCK-8 and flow cytometry, respectively.
PD98059 significantly abrogated the effects of CCL21/CCR7
on cell proliferation and the G2/M phase progression (Figure 7
and Table 2, respectively). PD98059 also abolished the influence
of CCL21/CCR7 on the expression of P-ERK, cyclin A, cyclin
B1, and CDK1 (Figure 8). In addition, PD98059 alone had a
significant inhibitory effect on the cell proliferation, the G2/M
phase progression and the expression of P-ERK, cyclin A, and
cyclin B1 (Figure 7, Table 2, and Figure 8, respectively).
P-ERK, induced by CCL21/CCR7, interacts with cyclin A,
cyclin B1, and CDK1. To further identify whether there is an
interaction between P-ERK and cyclin A, cyclin B1, or CDK1,
coimmunoprecipitation was performed. A549 and H460 cells in
the absence or presence of CCL21 for 24 h were subjected to
immunoprecipitation with antibodies against P-ERK or IgG,
followed by Western blotting for cyclin A, cyclin B1, and CDK1. A
pronounced, specific interaction between P-ERK and cyclin A,
cyclin B1, or CDK1 was observed, especially when the cells were
treated with CCL21 for 24 h (Figure 9a). Reciprocal immuno-
precipitation with antibodies against cyclin A, cyclin B1, CDK1,
or IgG was assessed by Western blotting for P-ERK, and again,
the interaction between P-ERK and cyclin A, cyclin B1, or CDK1
was salient, especially in the presence of CCL21 (Figure 9b). A549
and H460 cells in the absence or presence of PD98059 for 1 h
were subjected to immunoprecipitation with antibodies against P-
ERK or IgG, followed by Western blotting for cyclin A, cyclin B1,
Figure 2. Effect of CCL21 at various concentrations on proliferation of A549 and H460 cells. A549 (A) and H460 (B) cells were treated with
CCL21 (50, 100 or 200 ng/mL) for 24, 48, or 72 h, and cell vitality was estimated using the CCK-8 assay. Each bar represents the mean 6 SD of three
independent experiments. **p,0.01, compared with cells treated with CCL21 (50 ng/mL).
doi:10.1371/journal.pone.0021119.g002
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B1, or CDK1 was weakened in response to PD98059 exposure
(Figure 9c).
Discussion
Several studies have documented that the activation of CCR7 is
responsible for mediating survival of certain cancer cell lines by
promoting migration and proliferation or by inhibiting apoptosis
[33,35–42]. However, the role of CCR7 in the proliferation of
human NSCLC cells has not been well documented. In the
present study, we confirmed that the CCL21/CCR7 interaction
can significantly enhance human NSCLC cell proliferation in a
time-dependent manner, involving the upregulation of cyclin A,
cyclin B1, and CDK1, possibly via the ERK, but not the Akt,
pathway.
Consistent with previous studies using different cell models
[16,37,40], the activation of CCR7 with CCL21 promoted cell
proliferation. In contrast to our current findings, a prior study
suggested that murine CCL21 had no significant action on the
proliferation of A549 cells [44]. A possible explanation for the
discrepancy would be that mouse CCL21 can interact with
CXCR3 but not CCR7, whereas human CCL21 can bind CCR7
but not CXCR3 [45]. This suggests that activation of CXCR3
does not affect proliferation of A549 cells.
Traditionally, the cell cycle is segregated into four phases: DNA
replication occurs during S phase, and chromosome segregation
occurs during M phase. The S and M phases are separated by the
so-called gap phases, G1 (before DNA replication) and G2 (before
mitosis). We demonstrated that CCL21/CCR7 significantly
altered cell cycle distribution such that more cells populated the
G2/M phase. No significant differences were observed regarding
the distribution of cells in the G0/G1 and S phases.
The cell cycle is regulated by cyclins and CDKs. D-type cyclins
are regarded as key regulators of G1 progression [46]. Cyclin E is
required for the G1/S transition [47,48] and cyclin A is essential
for progression through the S phase [49,50]. Both cyclin A and the
B-type cyclins associate with CDK1 to promote entry into mitosis
[51,52]. In this study, both protein and mRNA levels of cyclin A,
cyclin B1, and CDK1 were significantly upregulated when cells
were treated with CCL21 for 24 h. This indicates that CCL21/
CCR7 accelerates the G2/M phase progression to promote cell
proliferation. No significant differences in cyclin D1 or cyclin E
expression levels were measured, indicating that CCL21/CCR7
has no significant effect on the G0/G1 phase or the G1/S
transition. This finding demonstrates for the first time that
CCL21/CCR7 has an impellent effect on cell cycle progression
involving the G2/M phase.
Several studies using other cell types have indicated that
activation of CCR7 is associated with enhanced cell survival via
increased phosphorylation of ERK, JNK, or Akt [16–20,33,35–
42]. We examined whether CCL21/CCR7 may enhance the
expression of MAPK components and Akt in A549 and H460
cells. Our results suggested that CCL21/CCR7 enhanced the
phosphorylation of ERK but not JNK, p38, or Akt. These findings
are inconsistent with previously published reports that suggested a
Figure 3. Effect of CCL21/CCR7 on proliferation of A549 and H460 cells. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL)
for 24, 48, or 72 h, and cell vitality was estimated using the CCK-8 assay. Each bar represents the mean 6 SD of three independent experiments.
**p,0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.g003
Table 1. Effect of CCL21/CCR7 on cell cycle distribution in
A549 and H460 cells.
Group G0/G1 phase S phase G2/M phase
Mean ± SD (%) Mean ± SD (%) Mean ± SD (%)
(A549) Control 74.3569.67 23.42612.29 2.2362.82
(A549) CCL21 66.9261.23 21.6062.91 11.4862.64*
(A549) siCCR7-
CCL21
69.08610.08 23.9069.28 6.6062.46
(A549) siCCR7 75.7362.32 18.0963.67 6.1962.45
(H460) Control 61.5062.70 31.3363.41 7.1761.63
(H460) CCL21 60.3866.85 27.0864.13 12.5462.75*
(H460) siCCR7-
CCL21
69.2564.99 21.4063.23 6.0262.53
(H460) siCCR7 67.5762.40 28.0064.10 4.6361.20
A549 and H460 cells were treated with CCL21 (100 ng/mL) for 24 h, and cell
cycle distribution was estimated using flow cytometry. Data were present as
mean 6 SD of three independent experiments.
*p,0.05, compared with control cells.
doi:10.1371/journal.pone.0021119.t001
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[16,19]. A separate study indicated that Akt is possibly upstream of
ERK [43]. We found that CCL21/CCR7 still could significantly
upregulate the expression of P-ERK after the cells were treated
with LY294002 for 1 h. Because LY294002 selectively inhibits
PI3K to prevent downstream activation of Akt, our results strongly
Figure 4. Effect of CCL21/CCR7 on the expression of cyclins and cyclin-dependent kinases in A549 and H460 cells. A549 (A) and H460
(B) cells were treated with CCL21 (100 ng/mL) for 24 h, and the protein (a) and mRNA (b) levels of cyclins A, B1, D1, and E and of CDK1 were
estimated using Western blot (a) and real-time PCR (b). Each bar represents the mean 6 SD of three independent experiments. *p,0.05 or **p,0.01,
compared with control cells.
doi:10.1371/journal.pone.0021119.g004
Figure 5. Effect of CCL21/CCR7 on the expression of ERK, JNK, p38, and Akt in A549 and H460 cells. A549 (A) and H460 (B) cells were
treated with CCL21 (100 ng/mL) for 12, 24, or 48 h, and normal and phosphorylated (P-) expression levels were estimated by Western blot. Each bar
represents the mean 6 SD of three independent experiments. *p,0.05 or **p,0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.g005
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H460 (B) cells were treated with CCL21 (100 ng/mL) for 24 h after LY294002, a selective inhibitor of PI3K that consequently prevents activation of the
downstream Akt, was applied for 1 h. The expression of P-ERK was estimated using Western blot. Each bar represents the mean 6 SD of three
independent experiments. **p,0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.g006
Figure 7. Effect of CCL21/CCR7 on proliferation of A549 and H460 cells after inhibiting ERK activation. A549 (A) and H460 (B) cells were
treated with CCL21 (100 ng/mL) for 24, 48, or 72 h after PD98059, a selective inhibitor of MEK that disrupts activation of downstream ERK, was
applied for 1 h. Cell vitality was estimated using the CCK-8 assay. Each bar represents the mean 6 SD of three independent experiments. *p,0.05 or
**p,0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.g007
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between CCL21/CCR7 and ERK. This is in concordance with a
previous report [53]. The reason for these discrepancies remains
unclear.
Since CCL21/CCR7 was capable of increasing the expression
of P-ERK, we sought to determine whether there is an interaction
between P-ERK and cyclin A, cyclin B1, or CDK1. Coimmuno-
precipitation and reciprocal immunoprecipitation results strongly
suggested an interaction between P-ERK and cyclin A, cyclin B1,
or CDK1, especially in the presence of CCL21. This interaction
could be weakened by inhibiting ERK with PD98059. In addition,
PD98059 abolished the effect of CCL21/CCR7 on A549 and
H460 cell proliferation and G2/M phase progression, as well as
downregulating the expression of P-ERK, cyclin A, cyclin B1, and
CDK1. These results demonstrate that the effect of CCL21/
CCR7 on cell proliferation and upregulation of cyclin A, cyclin
B1, and CDK1 may occur via the ERK pathway in human
NSCLC cells.
This study suggests that activation of CCR7 with CCL21 can
significantly promote proliferation of NSCLC cells in a time-
dependent manner involving cyclin A, cyclin B1, and CDK1,
possibly via the ERK, but not the Akt, pathway. This information
may help clarify the mechanisms of cancer cell survival and
identify potential targets for treatment of NSCLC.
Materials and Methods
Cell culture and reagents
A549 and H460 cell lines from our previous published paper
[32] were cultured in RPMI-1640 or DMEM-F12 supplemented
with 10% HyClone fetal bovine serum (FBS) (ThermoFisher
Scientific, Fremont, CA, USA) in an atmosphere of 5% CO2 at
37uC. Cells were grown in 75 cm
2 culture flasks and harvested in a
solution of trypsin-EDTA at the logarithmic growth phase.
Cyclin A, cyclin B1, cyclin D1, cyclin E, CDK1, P-ERK, ERK,
P-JNK, JNK, P-p38, p38, P-Akt, Akt, IgG, and b-actin mouse or
rabbit monoclonal antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Recombinant human
CCL21 was purchased from Pepro Tech (Rocky Hill, NJ, USA).
siCCR7 and Lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA, USA). Cell Counting Kit-8 (CCK-8) was
purchased from Dojindo Laboratories (Beijing, China). PD98059
and LY294002 were obtained from Sigma (St. Louis, MO, USA)
and used at 50 mM or 100 mM (final concentrations), respectively,
in accordance with previous reports [40,54]. Protein A/G beads
were obtained from Beyotime (Haimen, China).
siRNA treatment of cells
A549 and H460 cells were plated onto 6 cm
2 cell culture dishes
and grown to 30–50% confluence before transfection with
Lipofectamine 2000 as previously described [55]. The transfection
efficiency was assessed by flow cytometry. Efficiencies of siCCR7
and non-silencing control siRNA were tested using Western blot
and RT-PCR. The sequences of siCCR7 and control siRNA were:
CCR7, 59-GCGUCAACCCUUUCUUGUATT-39 and 39-UA-
CAAGAAAGGGUUGACGCAG-59; control, 59-UUCUCCGA-
ACGUGUCACGUTT-39 and 39-ACGUGACACGUUCGGA-
GAATT-59.
Cell proliferation assay
CellproliferativeactivitieswereexaminedusingCCK-8.A549and
H460 cells were seeded onto 96-well plates (1000 cells/well) and
treated with CCL21 for 0, 24, 48, or 72 h. After treatment, CCK-8
was added to each well according to the manufacturer’s instructions
and incubated for 4 h at 37uC. The optical density (OD) value of
each well was measured using a microplate reader (Spectra Thermo,
Ma ¨nnedorf, Switzerland) with a test wavelength of 450 nm.
Cell cycle analysis
After treatment with CCL21 for 24 h, cells were harvested and
washed twice with cold phosphate-buffered saline (PBS) and fixed
in 75% ethanol for 2 h at 4uC. The fixed cells were washed twice
with 500 mL of cold PBS. Cells then were stained with 500 mLo f
propidium iodide (PI) staining solution (50 mg/mL PI, 0.1%
Triton X-100, 200 mg/mL DNase-free RNase in PBS) for 30 min
at room temperature in the dark. Ten thousand events per sample
were acquired using a FACS-scan flow cytometer (Becton-
Dickinson, San Jose, CA, USA), and the percentage of cells in
G0/G1, S, and G2/M phases of the cell cycle were determined
using Modfit LT 3.0 (Becton-Dickinson).
Western blot analysis
After treatment with CCL21 for 24 h, cells were extracted with
lysis buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 2 mg/mL
aprotinin and 1 mM PMSF) for 30 min at 4uC. Extracts were
centrifuged at 12,0006 g for 15 min at 4uC. Supernatants
containing total protein then were harvested. Aliquots, each
containing 50 mg protein, were separated by 10% SDS-PAGE and
transferred to PVDF membranes at 55 V (cyclin A, cyclin B1, P-
Akt, Akt) or 40 V (the others) for 2.5 h at low temperature. The
membranes were blocked in 5% skim milk for 2 h, and proteins
were detected using monoclonal antibodies at 1:1000 (P-JNK,
JNK, P-p38, p38 and b-actin) or 1:200 (the others) dilution
overnight at 4uC. Proteins were visualized using anti-mouse or
anti-rabbit IgG conjugated with horse radish peroxidase (HRP) at
1:6000 or 1:8000 dilution for 2 h at room temperature,
respectively. Bands were imaged with an EC3 Imaging System
(UVP LLC, Upland, CA, USA), and the OD was measured using
ImageJ (NIH, Bethesda, MD, USA). The OD difference between
tested proteins and b-actin of the same sample was calculated as
relative content and expressed graphically.
Table 2. Effect of CCL21/CCR7 on cell cycle distribution after
inhibiting ERK in A549 and H460 cells.
Group G0/G1 phase S phase G2/M phase
Mean ± SD (%) Mean ± SD (%) Mean ± SD (%)
(A549) Control 80.4960.67 14.5761.48 4.9460.91
(A549) CCL21 68.5863.17 20.2160.40 11.4862.64**
(A549) PD98059-
CCL21
73.0666.94 22.1167.42 4.8460.58
(A549) PD98059 76.65611.28 24.6465.83 2.0560.31*
(H460) Control 65.7361.72 27.9560.94 6.3361.76
(H460) CCL21 58.5868.68 29.4166.16 12.0162.70**
(H460) PD98059-
CCL21
67.8063.00 26.9163.17 5.2961.29
(H460) PD98059 67.0762.17 30.5063.02 2.4361.18*
A549 and H460 cells were treated with CCL21 (100 ng/mL) for 24 h after
PD98059, a selective inhibitor of MEK that disrupts activation of downstream
ERK, was used for 1 h. After treatment, cell cycle distribution was estimated
using flow cytometry. Data were present as mean 6 SD of three independent
experiments.
*p,0.05 or
**p,0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.t002
CCL21/CCR7 promotes G2/M Phase Progression
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21119RT-PCR and real-time PCR
Total RNA was isolated from cells using TRIzol (Invitrogen)
according to the manufacturer’s instructions. b-Actin was used as an
internal control. To determine the efficiencies of siCCR7 and control
siRNA, semi-quantitative RT-PCR was performed on a G-STORM
thermal cycler (GRI Ltd, Byfleet, UK) using the TaKaRa RNA PCR
Kit (AMV) Ver.3.0 (TaKaRa, Dalian, China). PCR primers were as
follows: CCR7 F: 59-GAGGCTATTGTCCCCTAAACC-39,R :5 9-
TGGAGGACAGTGAAGAAAACG-39. The CCR7 amplicon
length was 305 bp. b-actin F: 59-AAATCGTGCGTGACATTAA-
39,R :5 9-CTCGTCATACTCCTGCTTG-39.T h eb-actin ampli-
con length was 513 bp. The heat cycling conditions were as follows:
30 cycles of 40 s each, including denaturation at 95uC, annealing at
53uC, and extension at 72uC.
Real-time PCR was performed on an ABI Prism 7900HT Fast
System (Applied Biosystems, Foster, CA, USA) using SYBR
Premix Ex Taq II (TaKaRa). Amplifications were carried out in a
total volume of 20 mL and cycled 40 times after initial
denaturation (95uC for 30 s) with the following parameters:
95uC for 5 s and 60uC for 30 s. b-actin F: 59-AGCACA-
GAGCCTCGCCTTTG-39,R :5 9-ACATGCCGGAGCCGTT-
GT-39. The b-actin amplicon length was 107 bp. Other primer
sequences have been published in another study [56]. The
reliability of PCR results was supported by analyzing the
dissociation curve. Real-time PCR data were calculated using
the 2
2DDCT method on the SDS 2.4 software package (Applied
Biosystems) [57].
Coimmunoprecipitation
After treatment with CCL21 for 24 h, cells were extracted with
lysis buffer (10 mM KCl, 1.5 mM MgCl2, 10 mM HEPES
[pH 7.9], 1 mM PMSF, 1 mM DTT) and homogenized for
Figure 8. Effect of CCL21/CCR7 on the expression of P-ERK, cyclin A, cyclin B1, and CDK1 after inhibiting the activation of ERK. A549
(A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for 24 h after PD98059, a selective inhibitor of MEK that disrupts activation of
downstream ERK, was applied for 1 h. The expression levels of these components were estimated using Western blot. Each bar represents the mean
6 SD of three independent experiments. *p,0.05 or **p,0.01, compared with control cells.
doi:10.1371/journal.pone.0021119.g008
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15 min at 4uC, and the supernatants containing total protein were
harvested. Equal amounts of protein were exposed to antibodies
against P-ERK, IgG, cyclin A, cyclin B1, or CDK1, which were
immobilized on protein A/G beads. Following 3 h incubation at
4uC with gentle rotation, beads were washed extensively five times
with lysis buffer, boiled, and microcentrifuged. Proteins were
detected with antibodies against P-ERK, cyclin A, cyclin B1, or
CDK1 by Western blot.
Statistical analysis
Data were analyzed using SPSS 16.0 software. One-way
analysis of variance (ANOVA) was used to evaluate the differences
between groups with various treatments, and the least significant
difference (LSD) test or Dunnett T3 test was used for post hoc
subgroup analysis. Polynomial contrast was used for trend analysis.
All data are presented as the mean 6 SD of three independent
experiments. Results were considered statistically significant for
p,0.05. N-fold values for gene expression change up to 0.5 and
below 2 were taken as nonsignificant in accordance with values
obtained from negative control genes [57,58].
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